鼻内氢吗啡酮治疗儿童急性疼痛:一项先导研究
该前瞻性剂量滴定先导研究纳入35名4至17岁、因中度至重度疼痛需肠外阿片类药物的其他方面健康儿童。所有患者接受鼻内氢吗啡酮初始剂量0.03 mg/kg,在15分钟和30分钟评估是否需要追加镇痛,若需要则每次追加0.015 mg/kg。15、11、9名儿童分别需要总剂量0.03、0.045、0.06 mg/kg。各剂量组患者在完成剂量滴定给药后5至15分钟内疼痛评分绝对值下降≥3/10且百分比降幅>40%。85.7%的患者镇痛持续时间(即至给予救援镇痛药的时间)>1小时,3名(8.6%)患者在给药后<1小时需要救援镇痛药,未发生重大不良事件。
要点
- 在4至17岁急诊中度至重度疼痛儿童中,鼻内氢吗啡酮初始剂量0.03 mg/kg,15分钟和30分钟评估后按需追加0.015 mg/kg,总剂量可达0.06 mg/kg。
- 35名儿童中,15、11、9名分别需要总剂量0.03、0.045、0.06 mg/kg。
- 各剂量组在完成剂量滴定给药后5至15分钟内疼痛评分绝对值下降≥3/10且百分比降幅>40%。
- 85.7%的患者镇痛持续时间>1小时;3名(8.6%)患者在给药后<1小时需要救援镇痛药。
- 未观察到重大不良事件。
适用人群与场景
- 其他方面健康、4至17岁、因中度至重度疼痛需肠外阿片类药物的儿童,就诊于急诊科。
诊断标准与关键阈值
- 中度至重度疼痛且需肠外阿片类药物的其他方面健康儿童,年龄4至17岁。
处置流程与药物剂量
- 所有患者接受鼻内氢吗啡酮初始剂量0.03 mg/kg。
- 在15分钟和30分钟评估是否需要追加镇痛,若需要则每次追加0.015 mg/kg。
- 评估救援镇痛药需求、疼痛强度及不良事件,直至氢吗啡酮给药后6小时,或直至患者出院、接受针对疼痛状况的操作或接受救援镇痛药。
研究设计与关键结果
- 前瞻性剂量滴定先导研究,纳入35名4至17岁急诊中度至重度疼痛儿童。
- 15、11、9名儿童分别需要总剂量0.03、0.045、0.06 mg/kg。
- 各剂量组患者在完成剂量滴定给药后5至15分钟内疼痛评分绝对值下降≥3/10且百分比降幅>40%。
- 85.7%的患者镇痛持续时间(即至给予救援镇痛药的时间)>1小时;3名(8.6%)患者在给药后<1小时需要救援镇痛药。
- 未需要救援镇痛药的患者在出院或疼痛状况得到治疗前仅有轻度或无疼痛。
- 未发生重大不良事件。
证据类型、等级与局限
- 证据类型:前瞻性剂量滴定先导研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为鼻内氢吗啡酮可使儿童疼痛强度快速、有临床意义且常持续下降;未观察到重大不良事件。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to describe the analgesic efficacy, duration of analgesia, and adverse event profile associated with intranasal hydromorphone in children with acute pain presenting to an emergency department.
METHODS: Prospective dose titration pilot study of otherwise healthy children 4 to 17-years-old with moderate to severe pain who required a parenteral opioid. All patients received an initial intranasal hydromorophone dose of 0.03 mg/kg. The need for additional analgesia was assessed at 15 and 30 min; an additional 0.015 mg/kg was given at each assessment, if required. Need for rescue analgesic, pain intensity and adverse events were assessed until 6 h after hydromorphone administration or until patients were discharged, underwent a procedure to treat their painful condition, or received a rescue analgesic.
RESULTS: We enrolled 35 children. Fifteen, 11, and 9 children required a total dose of 0.03, 0.045, and 0.06 mg/kg, respectively. Patients in each dose group experienced an absolute decrease in pain score of ≥3/10 and percent reduction >40% within 5-15 min of completing dose-titration administration of hydromorphone. Duration of analgesia (i.e. time until rescue analgesic administered) >1 h was observed in 85.7% of patients. Patients not requiring rescue analgesics had mild or no pain until discharged or their painful conditions were treated. Three (8.6%) patients required a rescue analgesic <1 h after hydromorphone administration. There were no major adverse events.
CONCLUSIONS: Intranasal hydromorphone led to rapid, clinically significant and frequently sustained decreases in pain intensity in children. No major adverse events were observed in this preliminary sample. Clinical Trials Registration Number: NCT02437669.
参考来源
- Tsze DS, Pan SS, DePeter KC, et al. Intranasal hydromorphone for treatment of acute pain in children: A pilot study. Am J Emerg Med. 2019. PMID: 30902361. doi:10.1016/j.ajem.2019.03.013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。